In contrast, CPT1 enzyme activity was significantly enhanced in MDA-MB-231 breast cancer cells at both the 100 and 500 ng/ml doses of PRL, resulting in 21.2% and 18.8% increases, respectively, compared to untreated cells (Figure 2C; p < 0.02). This evidence concerns the gene CPT1A and breast cancer.